Document is current
Any future updates will be listed below
-
Authors
Wee, Kathleen
Yang, Kevin C.
Schaeffer, David F.
Zhou, Chen
Leung, Emily
Feng, Xiaolan
Laskin, Janessa
Marra, Marco A.
Loree, Jonathan M.
Gorski, Sharon M.
-
Funding
Funding for this research was provided by:
Canadian Cancer Society (#707495)
2017 Neuroendocrine Tumor Research Foundation – AACR Grant (#17-60-33-GORS)
BC Cancer Foundation
Genome British Columbia (project B20POG)
Michael Smith Health Research BC (Professional Investigator Award)
- License Information
-
More Information
Article History
Received: 9 August 2024
Accepted: 29 April 2025
First Online: 6 May 2025
Declarations
:
: DFS declares consultancy work outside of the submitted work from Alimentiv, Pfizer, Merck, Diaceutics, Astellas, Bayer; and Stock Ownership in Satisfai Health Inc.
: This work was approved by and conducted in accordance with guidelines and regulations of the University of British Columbia—BC Cancer Research Ethics Board and harmonized with Simon Fraser University Research Ethics Board (H16-01577). The cohort of 28 patients gave informed consent and enrolled in the POG program registered under clinical trial number NCT02155621.
